Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.
Ipriflavone, 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one, was administered orally for 12 weeks to male rats with prednisolone-induced osteoporosis. Microdensitometric analysis of a roentgenograph of the femurs revealed that ipriflavone increased the density of the distal metaphysis dose-dependently and tended to increase the density of the diaphysis. It also inhibited dose-dependently the decrease in the mechanical strength of the tibia, breaking strain and breaking energy, and the fractional content of ash in femurs. These results indicate that ipriflavone markedly suppresses bone resorption at the metaphysis where the content of trabecular bone with a rapid turnover rate is high, and possibly inhibits bone reduction at the diaphysis.
D000818:Animals; D001842:Bone and Bones / Q000473:pathology / Q000503:physiopathology; D002116:Calcitonin / Q000097:blood; D002118:Calcium / Q000097:blood; D005419:Flavonoids / Q000627:therapeutic use*; D007529:Isoflavones / Q000627:therapeutic use*; D008297:Male; D008903:Minerals / Q000378:metabolism; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011239:Prednisolone; D051381:Rats; D011919:Rats, Inbred Strains; D013718:Tensile Strength
D005419:Flavonoids; D007529:Isoflavones; D008903:Minerals; D010281:Parathyroid Hormone; D010758:Phosphorus; C018986:ipriflavone; D002116:Calcitonin; D011239:Prednisolone; D002118:Calcium